Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
Suzanne I AnjieMelanie S HulshoffGeert R A M D'HaensPublished in: Expert opinion on biological therapy (2023)
Anti-TNF agents will remain a cornerstone of IBD treatment in the coming decade. Progress will be made in biomarkers for the prediction of response and individualized dosing regimens. The advent of subcutaneous infliximab challenges the need for concomitant immunosuppression.
Keyphrases